HONG KONG, Jan. 09, 2026 — Ping An Biomedical Co., Ltd (NASDAQ: PASW), also known as “Ping An Bio,” has announced the signing of a non-binding memorandum (the “Investment Memorandum”) with Future Biotechnology Group Co., Ltd (hereinafter referred to as “Future Biotechnology Group”).
The Investment Memorandum details an initial cash investment of US$30 million, alongside subsequent acquisitions totaling US$60 million, payable through a combination of cash and newly issued shares (the “Consideration Shares”). These Consideration Shares will be held in escrow and disbursed based on specific performance milestones over a three-year assessment period, spanning from January 2026 to December 2028.
Performance Milestones
January 1, 2026 – December 31, 2026:
The target company is expected to achieve audited revenue of at least RMB 750 million.
January 1, 2027 – December 31, 2027:
The target company is expected to achieve audited revenue of at least RMB 1.3 billion.
January 1, 2028 – December 31, 2028:
The target company is expected to achieve audited revenue of at least RMB 2.3 billion.
The Consideration Shares are subject to adjustments based on the stipulated terms. Should the seller not meet the agreed performance targets during any assessment period, a portion of the shares designated for release in that period (equivalent to one-fifth of the total Consideration Shares) will be reduced according to a predefined formula. The company will then cancel these reduced Consideration Shares. Conversely, if the seller surpasses a performance target by over 50% in any given assessment period, the surplus revenue can be applied to compensate for any shortfalls from prior assessment periods.
Future Biotechnology Group operates as an innovative technology firm specializing in the biopharmaceutical industry. Its primary activities encompass biopharmaceutical research and development, genetic testing, medical device production, and pharmaceutical distribution. The company is also actively pursuing its “AI Intelligent Manufacturing” initiative, embedding artificial intelligence across critical domains like drug discovery, production workflows, and precision medicine to consistently boost R&D effectiveness and market readiness. Furthermore, the group maintains enduring and robust strategic alliances with numerous healthcare organizations.
Ping An Biomedical Co., Ltd affirmed that this strategic investment is consistent with its long-term vision of “technology empowering healthcare.” By fostering synergistic collaboration with Future Biotechnology Group, Ping An Bio aims to further consolidate biopharmaceutical R&D, clinical application, and industrial assets, thereby accelerating the widespread adoption of innovative technologies and strengthening its competitive standing within the industry.
As the biopharmaceutical sector shifts towards high-quality growth, industrial consolidation featuring distinct technological roadmaps, precise performance objectives, and strong incentive structures is anticipated to unleash significant long-term growth. This strategic investment positions Ping An Bio firmly for sustained expansion within the biopharmaceutical domain.
About Ping An Biomedical Co., Ltd
Ping An Biomedical Co., Ltd. functions as a comprehensive supply chain management provider for the apparel industry. Additionally, it is an innovative enterprise committed to offering advanced solutions in the fields of healthcare and biomedical technology.
Safe Harbor and Informational Statement
This press release includes “forward-looking” statements as defined by Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These declarations are issued in compliance with the “safe harbor” stipulations of the U.S. Private Securities Litigation Reform Act of 1995. Any statements herein that are not purely historical facts, including but not limited to the Company’s stated objectives, plans, and strategies, as well as those containing terms such as “believe,” “expect,” “anticipate,” “future,” “will,” “intend,” “plan,” “estimate,” or comparable phrases, constitute “forward-looking statements.” While the Company’s management considers these forward-looking statements to be reasonable, there is no assurance that such expectations will prove accurate. These statements are subject to various risks and uncertainties that could lead to the Company’s actual future outcomes differing substantially from current projections. Such forward-looking statements are susceptible to alteration due to numerous potential events or factors, not all of which are known to the Company. These may include, but are not limited to, the Company’s capacity to promptly and precisely adapt to evolving fashion trends and consumer tastes; managing risks associated with customer concentration; dependence on external parties for raw materials, manufacturing, and logistics; shifts in Chinese government policies; China’s broader economic climate and local market conditions; the Company’s potential for growth via strategic acquisitions and new site development; adherence to governmental regulations; legislative or regulatory changes; geopolitical occurrences; and other events or risks detailed in Ping An Biomedical Co., Ltd’s submissions to the U.S. Securities and Exchange Commission. All data presented in this press release is current as of its publication date, and Ping An Biomedical Co., Ltd disclaims any obligation to revise or update any forward-looking statement, unless mandated by relevant law.
CONTACT: For more information, please contact: Ping An Biomedical Co., Ltd. Email: corpsec@pingan365.vip Celestia Investor Relations Email: investors@celestiair.com
